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A B S T R A C T
Two new drugs, the CYP17 inhibitor abiraterone acetate and the androgen receptor (AR) antagonist en-
zalutamide, have recently shown to prolong OS prior chemotherapy or in docetaxel treated mCRPC patients,
using steroidal therapy or placebo as control group. Updated analyses underlined the role of these new agents
on two prostate-speciﬁc endpoints as radiographic progression-free survival (rPFS) and time to ﬁrst skeletal-
related event (tSRE). On the basis of these reports, we made an indirect comparison between abiraterone and
enzalutamide. We obtained a clinically but not signiﬁcant diﬀerence favouring enzalutamide over abiraterone
in terms of rPFS (HR 0.48, 95% CI 0.22–1.02). No signiﬁcant diﬀerence was shown in term of tSRE (HR 0.99,
95% CI 0.83–1.17). In conclusion, abiraterone and enzalutamide have both demonstrated to signiﬁcantly
delay the bone progression resulting in similar improvements in bone-related endpoints in patients with
mCRPC.
1. Introduction
Prostate cancer (PCa) is currently the second leading cause of
cancer-related deaths in men in the United States and the most common
cancer in elderly males in Europe (Arnold et al., 2015; Siegel et al.,
2017). Androgen deprivation therapies (ADT) represents the standard
ﬁrst line therapy for advanced prostate cancer. This treatment drives to
prostate-speciﬁc antigen (PSA) decrease and clinical improvements in
more than 90% of patients (Damber, 2005). Nevertheless, this ther-
apeutic approach is not curative and the majority of patients often
develop castration resistance. In the last years, the introduction of
highly eﬀective novel treatments has signiﬁcantly changed the man-
agement of metastatic castration resistant prostate cancer (mCRPC)
patients with an improved overall survival (OS) advantage. In parti-
cular, two new drugs the CYP17 inhibitor abiraterone acetate and the
potent androgen receptor (AR) antagonist enzalutamide were recently
shown to prolong OS prior chemotherapy or in docetaxel treated
mCRPC patients (de Bono et al., 2011; Ryan et al., 2015, 2013; Scher
et al., 2012; Beer et al., 2014).
Abiraterone acetate is an orally administered steroidal antiandrogen
derived from the structure of pregnenolone. It inhibits androgen bio-
synthesis blocking the hydroxylase and lyase activities of CYP17A with
10–30 fold stronger than ketoconazole (Rowlands et al., 1995) resulting
in virtually undetectable serum and intratumoral androgens production
in the adrenals, testes and prostate cancer cells (O’Donnell et al., 2004;
Barrie et al., 1994). Abiraterone is usually administered with pre-
dnisone to ameliorate the secondary increase of the adrenocorticotropic
hormone that can lead to excess mineralocorticoid synthesis (Attard
et al., 2012). Two randomized clinical Phase III trials (RCTs) demon-
strated that abiraterone improved OS compared with placebo. In the
COU-AA-301 trial (de Bono et al., 2011), 1195 patients previously
treated with docetaxel were randomized to abiraterone plus prednisone
or placebo plus prednisone. The primary endpoint of OS was met with
an improvement in OS of 3.9 months compared with placebo and a
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longer radiographic progression free survival (rPFS) (5.6 vs. 3.6
months) was also observed. In the COU-AA-302 trial, 1088 che-
motherapy-naïve patients were randomized to abiraterone plus pre-
dnisone or to placebo plus prednisone. The results showed a sig-
niﬁcantly longer OS in the abiraterone group (34.7 months vs 30.3
months) (Ryan et al., 2015) and a 8.2 month improvement in radio-
graphic progression free survival (rPFS). Abiraterone treatment was
also associated with better pain control from skeletal metastases, a
delay in development of SREs, and delayed radiological skeletal pro-
gression (Ryan et al., 2013).
Recently, in the placebo-controlled phase 3 trial LATITUDE, the
addition of abiraterone and prednisone to ADT signiﬁcantly increased
OS and rPFS in men with metastatic, castration-sensitive prostate
cancer. In particular, the median OS was signiﬁcantly longer in the
abiraterone group than in the placebo group (not reached vs. 34.7
months) while the median length of rPFS was 33.0 months in the
abiraterone arm and 14.8 months in the placebo arm (Higgins et al.,
2011). Similar results were obtained in STAMPEDE trial that showed an
improvement in overall and failure-free survival in locally advanced or
metastatic prostate cancer patients treated with ADT plus abiraterone
than those who received ADT alone. Data demonstrated that when
abiraterone (with prednisone) was added to ADT it improved the 3 year
survival rate to 83%, compared to 76% with ADT alone and, ad-
ditionally, the 3 year failure-free survival rate was of 75% in the
treatment arm vs 45% with standard therapy (Jüni et al., 2001).
Enzalutamide is an oral AR inhibitor that targets multiple steps in
the AR signaling pathway. In the randomized phase III AFFIRM study,
signiﬁcant improvements in survival versus placebo were observed
when enzalutamide was used as a treatment for patients with mCRPC
following prior treatment with docetaxel. Additional beneﬁts included
an increase in rPFS (8.3 vs. 2.9 months), a signiﬁcant delay in time to
ﬁrst SREs and improvement in several measures of pain and health-
related quality of life (Scher et al., 2012). Furthermore, in the phase III
PREVAIL study evaluating enzalutamide versus placebo in patients with
mCRPC, who had not received chemotherapy, the anti-androgen sig-
niﬁcantly decreased the risk of radiographic progression and death
(Beer et al., 2014). There were also signiﬁcant improvements in all
secondary and prespeciﬁed exploratory endpoints, including delayed
initiation of chemotherapy, reduction in risk of ﬁrst skeletal-related
event and a high percentage of patients with objective response com-
pared with placebo (Beer et al., 2014).
These RCTs that led to regulatory approval of abiraterone and en-
zalutamide in mCRPC have demonstrated that both drugs seems to have
beneﬁts on bone disease in terms of rPFS and time to SRE (tSRE) onset
(Table 1).
The aim of this systematic review was to conduct a meta-analysis of
RCTs to assess the impact of these two drugs on bone speciﬁc endpoints
(rPFS and tSRE) in mCRPC.
2. Methods
We have searched for RCTs including men with histologically or
cytologically proven metastatic castration resistant prostate cancer
(mCRPC). We include in our analysis trials in which prostate cancer
(PCa) were treated with Abiraterone, a steroidal CYP17A1 inhibitor, or
Enzalutamide, an androgen-receptor inhibitor regardless of prior che-
motherapy or chemotherapy naive. Abiraterone or Enzalutamide trials
were both compared to placebo. The outcomes are radiographic pro-
gression free survival (rPFS) and time to skeletal-related event (tSRE).
We excluded trials in which data were unavailable, ongoing studies and
studies with small sample size (less than 10 patients for arm). To
minimize the risk of bias, we excluded observational trials. For the
articles with multiple follow-up over time, we decided to choose the
most updated and methodically valid. Data extraction and assessment
was made independently by two diﬀerent authors (D.S, A.G.) and dis-
agreement were solved by discussion with another author (G.T). We
include article with cross-over between treatments, managing data ac-
cording to the arm where patients were originally randomized to. We
searched for RCTs using Medline (PubMed), Embase-databases and
Cochrane-Library up to December 2016, with no language restrictions.
The inclusion of relevant abstract from the American Society of Clinical
Oncology(ASCO), European Society of Medical Oncology (ESMO) or
SIUrO (Italian Society of Oncological Urology) was made. Other un-
published data were explored through the ClinicalTrials.gov site (www.
clinicaltrials.gov), the reference lists of selected RCTs and all the pre-
vious meta-analysis about abiraterone and/or enzalutamide (see sup-
plement 1). We made a quality analysis of selected trials following the
criteria reported in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins et al., 2011) including: allocation concealment;
blinding of participants, personnel and outcome assessors; incomplete
outcome data; sequence generation; elective outcome reporting; other
sources of bias. For each study we deﬁned “Yes” as at low risk of bias
and as “No” at high risk of bias. We deﬁne also “unclear” if there were
insuﬃcient data for a precise judgement. The risk of selective outcome
reporting bias was also evaluated by two independent reviewers (D.S.
and A.G.) and disagreement were solved by consensus.
Outcomes (rPFS and tSRE) were analysed using Hazard Ratio (HR),
with a 95% of conﬁdence interval (CI). For each study we ﬁrst com-
puted the logarithm of HR (logHR) and its logarithm of standard error
(logSE) to perform meta-analysis. Subsequently, in case of more than
one RCT for a comparison (abiraterone vs placebo or enzalutamide vs
placebo), ﬁrst we perform a standard meta-analysis to obtain the pooled
estimates (Jüni et al., 2001). An indirect meta-analysis is able to
maintain the randomization within a RCT and to compare outcomes
between diﬀerent treatments (Bucher et al., 1997; Glenny et al., 2005).
Since all studies evaluating enzalutamide or abiraterone use placebo as
control arm, we can use indirect meta-analysis to provide pooled
Table 1
Characteristics of the 6 clinical trials included in the meta-analysis.
Trial Setting Endpoint Hormone Control arm Patients (HT arm/
Control arm)
rPFS mo (HR) tSRE mo (HR) Time to pain deterioration mo
(HR)
Beer et al. (2014) PRE-CT rPFS, tSRE Enzalutamide Placebo 1717 (872/845) NR vs 3,9
(0,19)
31,1 vs 31.3
(0,72)
NA
de Bono et al. (2011) POST-CT rPFS Abiraterone Placebo/
Prednisone
1195 (797/398) 5,6 vs 3,6
(0,67)
NA NA
Fizazi et al. (2014) POST-CT tSRE Enzalutamide Placebo 1199 (800/399) NA 16,7 vs 13,3
(0,69)
NR vs 13,8
(0,56)
Logothetis et al.
(2012)
POST-CT tSRE Abiraterone Placebo/
Prednione
1195 (797/398) NA 25,0 vs 20,3
(0,61)
NA
Rathkopf et al. (2014) PRE-CT rPFS Abiraterone Placebo/
Prednione
1088 (546/542) 16,5 vs 8.2
(0,52)
NA NR – 23,7
(0,71)
Scheret al. (2012) POST-CT rPFS Enzalutamide Placebo 1199 (800/399) 8,3 vs 2.9
(0,40)
NA NA
rPFS: Radiographic progression-free survival; tSRE: Time to skeletal event; NR: Not yet reached; NA: Not applicable.
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estimates of HRs (rPFS and tSRE) for the indirect comparison between
abiraterone and enzalutamide. As regard the above mentioned indirect
comparison, if we assume ABIes as the estimate of the direct compar-
ison between abiraterone (pre and post CT setting) versus placebo and
ENZAes as the estimates of the direct comparison between En-
zalutamide (pre and post CT setting) versus placebo, we performed the
indirect comparison of enzalutamide versus placebo as follow: ENZA/
ABI_indirect (logHR) = ENZAes(logHR) – ABIes(logHR). If we consider
that variances are from diﬀerent studies, the indirect comparison var-
iance was computed as follow: Var (log ENZA/ABI_indirect) = (Var log
ENZAes) + (Var log ABIes) (Bucher et al., 1997; Glenny et al., 2005;
Lumley, 2002).
Heterogeneity between studies was explored using I-square and Chi-
square tests. If I-square value was higher than 75% it was considered as
at high risk of heterogeneity and meta-analysis was performed using
random eﬀect-based model of Der Simonian and Laird. If not, we used
Fig. 1. Flow diagram (CONSORT) for the meta–analysis included studies (according to the PRISMA statement).
Fig. 2. Forest plot Enzalutamide versus Placebo (rPFS).
Fig. 3. Forest plot Enzalutamide versus Placebo
(tSRE).
S. Rizzo et al. Critical Reviews in Oncology / Hematology 120 (2017) 227–233
229
the ﬁxed eﬀect-based Mantel-Haenszel model (Borenstein et al., 2008;
Higgins and Green, 2011). As regards the risk of bias across studies, we
performed a publication bias analysis using Egger’s test and a Funnel
Plot. All the p-values were considered as statistically signiﬁcant if
p < 0,05. The meta-analysis was performed according to the PRISMA
– guidelines for reporting of systematic reviews (Moher et al., 2010),
using Cochrane RevMan ver. 5.3 statistical software and Comprehen-
sive Meta – Analysis ver. 2.0 to assess the risk of publication bias (Eg-
ger’s Test).
3. Results
The search for literature identiﬁed in a total of 2107 records, of
which 247 were excluded because duplicates; 1692 records were ex-
cluded because meta-analyses, retrospective or phase I/II studies. A
total of 168 trials were assessed for eligibility and 162 were excluded
Fig. 4. Forest plot Abiraterone versus Placebo (rPFS).
Fig. 5. Forest plot Enzalutamide + Abiraterone (rPFS) versus Placebo.
Fig. 6. Forest plot Enza + Abi (tSRE) versus Placebo.
Fig. 7. Indirect comparisons between enzalutamide
and abiraterone.
Table 2
Summary of indirect comparison results.
Overall results (pooled) rPFS HR (95% CI) tSRE HR (95% CI) Time to pain deterioration HR (95% CI)
Abiraterone vs Placebo 0,59 (0,46–0,76) 0,61 (0,48–0,79) 0,71 (0,59–0,85)
Enzalutamide vs Placebo 0,28 (0,13– 0,57) 0,71 (0,63–0,80) 0,56 (0,41–0,78)
Enzalutamide + Abiraterone vs Placebo 0,41 (0,25–0,65) 0,69 (0,61– 0,77) 0,67 (0,57–0,79)
Enzalutamide vs Abiraterone 0,48 (0,22– 1,02) 0,99 (0,83–1,17) 0,79 (0,55–1,14)
rPFS: Radiographic progression-free survival; SRE: Time to skeletal event.
Fig. 8. Funnel plot for rPFS trials of the comparison abiraterone/enzalutamide versus
placebo.
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because no data about the principal outcomes of our meta – analysis
(rPFS and tSRE) were reported. Finally, a total of six studies met all the
inclusion/exclusion criteria and were included in the meta–analysis
(Fig. 1)
3.1. Direct comparisons
3.1.1. Enzalutamide vs placebo
Two RCTs enrolling 2916 patients evaluated enzalutamide vs pla-
cebo in mCRPC settings. Pooled results showed statistically signiﬁcant
diﬀerences in terms of rPFS (HR 0.28, 95% CI 0.13–0.57) (Fig. 2) and
tSRE (HR 0.71, 95% CI 0.63–0.80) (Fig. 3) favouring enzalutamide. A
trial evaluated the time to pain deterioration (HR 0.56, 95% CI
0.41–0.78).
3.1.2. Abiraterone vs placebo
Two RCTs enrolling 2283 patients investigated also abiraterone
versus placebo in the same PCa settings (pre and post CT). Pooled re-
sults showed a statistically signiﬁcant result in terms of rPFS (HR 0.59,
95% CI 0.46–0.76) (Fig. 4). As regard tSRE, only one RCT investigated
abiraterone versus placebo showing a statistically signiﬁcant advantage
favouring abiraterone (HR 0.61, 95% CI 0.48–0.79). Time to pain de-
terioration was also explored in one trial (HR 0.71, 95% CI 0.59–0.85).
3.1.3. Abiraterone/enzalutamide vs placebo
Since RCTs evaluating Enzalutamide and Abiraterone were com-
pared to Placebo and studies were consistent each other (similar in-
clusion criteria), we decided to perform a pooled comparison to un-
derline the global eﬀect of both new generation hormonal therapies
(enzalutamide and abiraterone) versus placebo. We showed pooled
signiﬁcant results both in term of rPFS (HR 0.41, 95% CI 0.25–0.65)
(Fig. 5) and tSRE (HR 0.69, 95% CI 0.61–0.77) (Fig. 6). Even in terms of
time to pain deterioration, both drugs showed to be superior if com-
pared to placebo (HR 0.67, 95% CI 0.57–0.79).
3.2. Indirect comparisons
3.2.1. Enzalutamide vs abiraterone
We use the meta – analytic technique to do an indirect comparison
between enzalutamide and abiraterone pooled results on rPFS and
tSRE. We obtained a clinically but not formally signiﬁcant diﬀerence
favouring enzalutamide over abiraterone in terms of rPFS (HR 0.48,
95% CI 0.22–1.02). No signiﬁcant diﬀerence was shown both in term of
tSRE (HR 0.99, 95% CI 0.83–1.17) and of time to pain deterioration
(HR 0.79, 95% CI 0.55–1.14) (Fig. 7; Table 2).
3.2.2. Risk of bias assessment
Publication bias test is required in a meta-analysis including at least
3 studies. In our analysis, Egger’s test was calculated only for the en-
zalutamide/abiraterone vs placebo comparisons (rPFS–4 trials, tSRE 3
trials) showing no statistical signiﬁcance (p = 0.16 and p = 0.1 re-
spectively) (Funnel Plots Figs. 8 and 9). The overall quality of included
trials was also investigated following the CONSORT checklist state-
ment. We reported an average good quality of all trials. In particular,
only two trials (Logothetis and Rathkopf) did not specify the rando-
mization procedures, but it is probably partially due to the fact that trial
by Logothetis is an updated report from de Bono original article in-
cluding the randomization information. The same would be for the
allocation concealment and for the blinding of patients and personnel
involved in the study. For the outcome blinding, Logothetis, Rathkopf
and Fizazi did not report any evaluation probably for the above men-
tioned reasons, with a higher likelihood of bias due to the type of
outcomes (quality of life area) considered in these trials. For incomplete
outcome data, only Fizazi reported high risk of bias due to 35% of drop-
outers. No signiﬁcant risk of bias detected for selecting reporting
(Figs. 10 and 11).
4. Discussion
This meta-analysis shows that, relative to placebo, enzalutamide
signiﬁcantly improves rPFS and delays occurrence of ﬁrst SRE in men
with mCRPC (pre and post CT). Similarly, abiraterone prolongs rPFS in
both chemo-naïve and post docetaxel treated patients and increases
tSRE in chemo-treated setting compared to placebo. Data regarding the
eﬀects of abiraterone in pre-docetaxel setting on the SRE events are
lacking. Furthermore, pooled analysis evaluating the impact of both
agents on skeletal endpoints still demonstrated a signiﬁcant advantage
in treated population vs placebo in terms of rPFS and tSRE.
These results demonstrate that the role of abiraterone and en-
zalutamide are evolving.
The results from LATITUDE and STAMPEDE are certainly im-
pressive and unambiguous and reshape treatment algorithms for pros-
tate cancer. Indeed, abiraterone with conventional hormone therapy
should become a new standard of care for men with high-risk, meta-
static disease. In addition to being associated with survival beneﬁts in
patients with mCRPC, abiraterone and enzalutamide has shown
Fig. 9. Funnel plot for tSRE trials of the comparison abiraterone/enzalutamide versus
placebo.
Fig. 10. Risk of bias graph according to review au-
thors’ judgements.
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consistent eﬃcacy beneﬁts in bone metastatic disease, further sup-
porting its broad use in this indication. It is unsurprising that treatments
that are globally active in prostate cancer are similarly active in skeletal
outcomes, but it is unclear if these eﬀects on bone-related endpoints
may be secondary to a systemic control of the disease, or direct on bone
microenvironment. In this regard, a direct bone anabolic and an anti-
resorptive eﬀect of abiraterone has been previously demonstrated both
in vitro and in mCRPC patients (Iuliani et al., 2015). In particular, our
group found that abiraterone have a signiﬁcant inhibitory eﬀect on
human primary osteoclasts function and promoted osteoblast diﬀer-
entiation and bone matrix deposition (Iuliani et al., 2015). Such evi-
dence aquired a particular interest given results from LATITUDE and
STAMPEDE that in near future will lead to an signiﬁcant extention of
the patient’s life under androgen deprivation treatment. From this
perspective abiraterone treatment could exert additional positive eﬀect
on limiting Cancer Treatment Induced Bone Loss (CTIBL) due to hor-
monal deprivation.
No data about the direct eﬀect of enzalutamide treatment on bone
microenvironment are reported, but it could be interesting to evaluate
its potential speciﬁc action on bone cells.
Despite these evidences, the indirect comparison between en-
zalutamide and abiraterone have shown an advantage favoring en-
zalutamide only in term of rPFS very close to the statistical signiﬁcance.
A possible explanation of this result is that abiraterone is co-ad-
ministrated with prednisone, an active agent in the treatment of ad-
vanced prostate cancer. The activity of prednisone as a single agent has
been well characterized, even if the mechanism by which it exerts its
eﬀect on prostate cancer is at least partially understood. Prednisone was
eﬀective, for example, in the control arm of the pre-chemotherapy
COU-AA-302 study of abiraterone/prednisone versus prednisone-alone.
In that study, 24% of patients receiving prednisone 10 mg daily
achieved a> 50% PSA response rate, with a PFS of 8.1 months (Ryan
et al., 2013). Conversely, in enzalutamide trials pre (PREVAIL) and post
CT (AFFIRM), only 3% and 2% of the control group (placebo) had
a> 50% PSA decline respectively. In our opinion, the diﬀerent control
group for abiraterone (prednisone) and enzalutamide (placebo) may
represent an explanation of this diﬀerence in term of rPFS. Moreover,
this indirect comparison has other additional limitations. Firstly, the
inclusion of patients with visceral disease in the PREVAIL trial (11,2%
in enzalutamide arm and 12,5% in placebo group) were excluded from
the COU-AA-302 trial. Moreover, diﬀerences in PSA and number of
bone metastases at baseline in AFFIRM/PREVAIL trials compared to
COU-AA 301/302 could have generated some potential bias. Finally,
the impact of co-administration of bone target therapies may poten-
tially have inﬂuenced the ﬁnal results of our analyses but, un-
fortunately, the percentage of the patients treated with these agents are
available only for enzalutamide trials. To date, there is no strong lit-
erature data able to establish which would be the optimal management
of mCRPC. Probably factors such as the availability and costs must be
added to the tumor and individual patient characteristics. A new pos-
sibility may come from some promising biomarkers and the con-
solidated use of liquid biopsies that could play a signiﬁcant role in
mCRPC decision-making. Liquid biopsies could be a promising tool,
thanks to its manageability and mini-invasiveness, to study several
blood parameters such as circulating tumor cells, circulating tumor
DNA, or exosomes. In addition to prognosis (for example LDH/CTCs
combination) evaluation, from the study of these components re-
searchers could identify other negative predictive biomarkers of re-
sponse to the new generation hormone treatments, such as TMPRSS2:
ERG rearrangements, which would seem associated with Abiraterone
activity (Danila et al., 2011).
In conclusion, abiraterone and enzalutamide have both demon-
strated to signiﬁcantly delay the bone progression of the disease in
patients with mCRPC and to obtain similar improvements in bone-re-
lated endpoints conﬁrming the key role of these two agents in bone
mCRPC patients.
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